Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
59.1M
-
Shares change
-
-3.69M
-
Total reported value, excl. options
-
$621M
-
Value change
-
-$47.5M
-
Put/Call ratio
-
2.47
-
Number of buys
-
82
-
Number of sells
-
-75
-
Price
-
$10.52
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q1 2021
201 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q1 2021.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.1M shares
of 126M outstanding shares and own 46.71% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.75M shares), Palo Alto Investors LP (5.36M shares), STATE STREET CORP (5.33M shares), VANGUARD GROUP INC (3.56M shares), ALKEON CAPITAL MANAGEMENT LLC (2.67M shares), Delphi Management Partners VIII, L.L.C. (2.26M shares), WELLINGTON MANAGEMENT GROUP LLP (1.92M shares), MORGAN STANLEY (1.7M shares), RICE HALL JAMES & ASSOCIATES, LLC (1.56M shares), and TWO SIGMA INVESTMENTS, LP (1.49M shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.